Genetic allergen modification in the development of novel approaches to specific immunotherapy.
Identifieur interne : 002002 ( PubMed/Corpus ); précédent : 002001; suivant : 002003Genetic allergen modification in the development of novel approaches to specific immunotherapy.
Auteurs : S. Mutschlechner ; S. Deifl ; B. BohleSource :
- Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology [ 1365-2222 ] ; 2009.
English descriptors
- KwdEn :
- Allergens (genetics), Allergens (immunology), Allergens (therapeutic use), Animals, Cloning, Molecular, Humans, Hypersensitivity (immunology), Hypersensitivity (therapy), Immunoglobulin E (immunology), Immunotherapy, Recombinant Fusion Proteins (genetics), Recombinant Fusion Proteins (immunology), Recombinant Fusion Proteins (therapeutic use), Th2 Cells (immunology), Vaccines, Synthetic (genetics), Vaccines, Synthetic (immunology), Vaccines, Synthetic (therapeutic use).
- MESH :
- chemical , genetics : Allergens, Recombinant Fusion Proteins, Vaccines, Synthetic.
- chemical , immunology : Allergens, Immunoglobulin E, Recombinant Fusion Proteins, Vaccines, Synthetic.
- chemical , therapeutic use : Allergens, Recombinant Fusion Proteins, Vaccines, Synthetic.
- immunology : Hypersensitivity, Th2 Cells.
- therapy : Hypersensitivity.
- Animals, Cloning, Molecular, Humans, Immunotherapy.
Abstract
In the recent past, multiple allergens from relevant allergen sources have been cloned, sequenced and produced as recombinant proteins. The availability of recombinant allergens with immunological characteristics similar to their natural counterparts has improved the diagnosis of allergic disorders and increased our knowledge of the biochemical, structural and immunological characteristics of proteins with allergenic potential. Moreover, the use of defined recombinant proteins as vaccines substituting currently used total protein extracts from allergen sources may improve specific immunotherapy (SIT) of Type I allergy. In addition to producing well-defined batches of wild-type allergens, the recombinant technology offers the possibility to easily and selectively modify their properties or functions. Diverse modifications of allergens can be genetically engineered, e.g. variants with reduced IgE-binding capacity, multi-mers of single allergens or hybrids consisting of different allergens. Furthermore, allergens can be genetically fused with proteins that promote immune responses, which counterregulate the disease-eliciting T-helper type 2-dominated immune response in allergic individuals and may therefore, improve the efficacy of SIT. This review will introduce different concepts of allergen modification using genetic engineering to improve vaccines for SIT of Type I allergy.
DOI: 10.1111/j.1365-2222.2009.03317.x
PubMed: 19624521
Links to Exploration step
pubmed:19624521Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Genetic allergen modification in the development of novel approaches to specific immunotherapy.</title>
<author><name sortKey="Mutschlechner, S" sort="Mutschlechner, S" uniqKey="Mutschlechner S" first="S" last="Mutschlechner">S. Mutschlechner</name>
<affiliation><nlm:affiliation>Christian Doppler Laboratory for Immunomodulation, Department of Pathophysiology, Center for Physiology, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Deifl, S" sort="Deifl, S" uniqKey="Deifl S" first="S" last="Deifl">S. Deifl</name>
</author>
<author><name sortKey="Bohle, B" sort="Bohle, B" uniqKey="Bohle B" first="B" last="Bohle">B. Bohle</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19624521</idno>
<idno type="pmid">19624521</idno>
<idno type="doi">10.1111/j.1365-2222.2009.03317.x</idno>
<idno type="wicri:Area/PubMed/Corpus">002002</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002002</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Genetic allergen modification in the development of novel approaches to specific immunotherapy.</title>
<author><name sortKey="Mutschlechner, S" sort="Mutschlechner, S" uniqKey="Mutschlechner S" first="S" last="Mutschlechner">S. Mutschlechner</name>
<affiliation><nlm:affiliation>Christian Doppler Laboratory for Immunomodulation, Department of Pathophysiology, Center for Physiology, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Deifl, S" sort="Deifl, S" uniqKey="Deifl S" first="S" last="Deifl">S. Deifl</name>
</author>
<author><name sortKey="Bohle, B" sort="Bohle, B" uniqKey="Bohle B" first="B" last="Bohle">B. Bohle</name>
</author>
</analytic>
<series><title level="j">Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</title>
<idno type="eISSN">1365-2222</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Allergens (genetics)</term>
<term>Allergens (immunology)</term>
<term>Allergens (therapeutic use)</term>
<term>Animals</term>
<term>Cloning, Molecular</term>
<term>Humans</term>
<term>Hypersensitivity (immunology)</term>
<term>Hypersensitivity (therapy)</term>
<term>Immunoglobulin E (immunology)</term>
<term>Immunotherapy</term>
<term>Recombinant Fusion Proteins (genetics)</term>
<term>Recombinant Fusion Proteins (immunology)</term>
<term>Recombinant Fusion Proteins (therapeutic use)</term>
<term>Th2 Cells (immunology)</term>
<term>Vaccines, Synthetic (genetics)</term>
<term>Vaccines, Synthetic (immunology)</term>
<term>Vaccines, Synthetic (therapeutic use)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Allergens</term>
<term>Recombinant Fusion Proteins</term>
<term>Vaccines, Synthetic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Allergens</term>
<term>Immunoglobulin E</term>
<term>Recombinant Fusion Proteins</term>
<term>Vaccines, Synthetic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Allergens</term>
<term>Recombinant Fusion Proteins</term>
<term>Vaccines, Synthetic</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Hypersensitivity</term>
<term>Th2 Cells</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Hypersensitivity</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cloning, Molecular</term>
<term>Humans</term>
<term>Immunotherapy</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In the recent past, multiple allergens from relevant allergen sources have been cloned, sequenced and produced as recombinant proteins. The availability of recombinant allergens with immunological characteristics similar to their natural counterparts has improved the diagnosis of allergic disorders and increased our knowledge of the biochemical, structural and immunological characteristics of proteins with allergenic potential. Moreover, the use of defined recombinant proteins as vaccines substituting currently used total protein extracts from allergen sources may improve specific immunotherapy (SIT) of Type I allergy. In addition to producing well-defined batches of wild-type allergens, the recombinant technology offers the possibility to easily and selectively modify their properties or functions. Diverse modifications of allergens can be genetically engineered, e.g. variants with reduced IgE-binding capacity, multi-mers of single allergens or hybrids consisting of different allergens. Furthermore, allergens can be genetically fused with proteins that promote immune responses, which counterregulate the disease-eliciting T-helper type 2-dominated immune response in allergic individuals and may therefore, improve the efficacy of SIT. This review will introduce different concepts of allergen modification using genetic engineering to improve vaccines for SIT of Type I allergy.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19624521</PMID>
<DateCompleted><Year>2009</Year>
<Month>12</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised><Year>2009</Year>
<Month>10</Month>
<Day>28</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2222</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>39</Volume>
<Issue>11</Issue>
<PubDate><Year>2009</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</Title>
<ISOAbbreviation>Clin. Exp. Allergy</ISOAbbreviation>
</Journal>
<ArticleTitle>Genetic allergen modification in the development of novel approaches to specific immunotherapy.</ArticleTitle>
<Pagination><MedlinePgn>1635-42</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1365-2222.2009.03317.x</ELocationID>
<Abstract><AbstractText>In the recent past, multiple allergens from relevant allergen sources have been cloned, sequenced and produced as recombinant proteins. The availability of recombinant allergens with immunological characteristics similar to their natural counterparts has improved the diagnosis of allergic disorders and increased our knowledge of the biochemical, structural and immunological characteristics of proteins with allergenic potential. Moreover, the use of defined recombinant proteins as vaccines substituting currently used total protein extracts from allergen sources may improve specific immunotherapy (SIT) of Type I allergy. In addition to producing well-defined batches of wild-type allergens, the recombinant technology offers the possibility to easily and selectively modify their properties or functions. Diverse modifications of allergens can be genetically engineered, e.g. variants with reduced IgE-binding capacity, multi-mers of single allergens or hybrids consisting of different allergens. Furthermore, allergens can be genetically fused with proteins that promote immune responses, which counterregulate the disease-eliciting T-helper type 2-dominated immune response in allergic individuals and may therefore, improve the efficacy of SIT. This review will introduce different concepts of allergen modification using genetic engineering to improve vaccines for SIT of Type I allergy.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mutschlechner</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Christian Doppler Laboratory for Immunomodulation, Department of Pathophysiology, Center for Physiology, Medical University of Vienna, Vienna, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Deifl</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bohle</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2009</Year>
<Month>07</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Clin Exp Allergy</MedlineTA>
<NlmUniqueID>8906443</NlmUniqueID>
<ISSNLinking>0954-7894</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000485">Allergens</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>37341-29-0</RegistryNumber>
<NameOfSubstance UI="D007073">Immunoglobulin E</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000485" MajorTopicYN="N">Allergens</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006967" MajorTopicYN="N">Hypersensitivity</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007073" MajorTopicYN="N">Immunoglobulin E</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018418" MajorTopicYN="N">Th2 Cells</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>80</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>7</Month>
<Day>24</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>7</Month>
<Day>25</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>12</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">19624521</ArticleId>
<ArticleId IdType="pii">CEA3317</ArticleId>
<ArticleId IdType="doi">10.1111/j.1365-2222.2009.03317.x</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002002 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002002 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:19624521 |texte= Genetic allergen modification in the development of novel approaches to specific immunotherapy. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:19624521" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
This area was generated with Dilib version V0.6.33. |